insights_auto
Why is R7E0 up 10.65%?
Dive Deeperchevron_right
R7E0:FRA
Cybin Inc
€10.22
arrow_upward
+10.65%(+0.98) 1D
Oct 12, 10:00:00 PM GMT+2 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for R7E0...
Open
€10.22
High
€10.22
Low
€10.22
Avg. vol.
10.00
Volume
0.00
52-wk high
€10.22
52-wk low
€9.17
No. of employees
100
Open
€10.22
High
€10.22
Low
€10.22
Avg. vol.
10.00
Volume
0.00
52-wk high
€10.22
52-wk low
€9.17
No. of employees
100
News stories
From web sources and news partners
MarketBeat
·
2 days ago
Cybin Inc. (NASDAQ:HELP) Stock Has Average Target Price of $46.33
Kalkine Media
·
3 days ago
Which Milestones Sit Behind the Recent Rise in Cybin Shares?
Profile
Helus Pharma, also known formerly as Cybin IRL, is a Canadian pharmaceutical company that was led by CEO Doug Drysdale from 2020-2025, developing psychedelic drugs as medicines.
The company's drug candidates include psilocybin, HLP002, deupsilocin, deudimethyltryptamine, HLP005, and HLP006. Another drug that the company has developed is CYB210010.
As of January 2025, deupsilocin is in phase 3 clinical trials. The drug is one of the only other psychedelics besides Compass Pathways's COMP360 to have reached this late stage of clinical development.
In 2020, Helus Pharma acquired psychedelic pharmaceutical company Adelia Therapeutics. In late 2023, it acquired Small Pharma, the developer of SPL026 and SPL028. Helus Pharma was originally known as Cybin but changed its name in December 2025. Wikipedia
About Cybin Inc
CEO-
Employees100
Founded2019
HeadquartersToronto, Ontario, Canada
SectorPharmaceutical industry
Websitehelus.com